文献速递妇科

患者报告子宫肌瘤保留子宫手术后10年内的后续手术情况

Patient Report of Subsequent Uterine-Sparing Leiomyomata Procedures up to 10 Years.
PubMed 文献 · Obstet Gynecol · 2026-11-10

本研究对两项子宫肌瘤手术研究的817例参与者进行再联系,基线手术包括子宫肌瘤剔除术、子宫内膜消融术、腹腔镜超声引导射频消融(RFA)和子宫动脉栓塞术(UAE)。中位随访4.0-10.5年,204例(28.7%)接受了再次治疗,最常见为子宫切除术(n=94,46.1%)。与子宫肌瘤剔除术相比,RFA的再治疗率更高(HR 1.61,95% CI 1.08-2.40)。结论认为多数女性在保留子宫的子宫肌瘤手术后5-10年内可无需治疗。

要点

  • 817例参与者中,204例(28.7%)在基线保留子宫手术后接受了再次治疗。
  • 再次治疗中最常见为子宫切除术(n=94,46.1%),其次为子宫肌瘤剔除术(n=57,27.9%)。
  • 与子宫肌瘤剔除术相比,RFA的再治疗率更高(HR 1.61,95% CI 1.08-2.40)。

核心结论

  • 多数接受保留子宫的子宫肌瘤手术的女性可在5-10年内无需治疗。

研究设计与样本

  • 对两项子宫肌瘤手术研究的参与者进行再联系。
  • 共817例参与者,基线手术包括子宫肌瘤剔除术(n=469,66.0%)、子宫内膜消融术(n=90,12.7%)、RFA(n=96,13.5%)和UAE(n=56,7.9%)。
  • 基线手术时中位年龄39.7岁,再联系时中位年龄46.8岁,基线手术后随访4.0-10.5年。
  • 采用Kaplan-Meier曲线和Cox比例风险模型评估再治疗风险,Fisher精确检验分析基线手术与再治疗手术的关联。

主要发现

  • 204例(28.7%)接受了子宫肌瘤再治疗,最常见为子宫切除术(n=94,46.1%),其次为子宫肌瘤剔除术(n=57,27.9%)、UAE(n=26,12.7%)、子宫内膜消融术(n=12,5.9%)、MRI引导聚焦超声(n=9,4.4%)和RFA(n=6,2.9%)。
  • 基线手术后5年内,79.1%(95% CI 76.2-82.1%)无额外子宫手术;10年内,64.1%(95% CI 57.7-71.2%)无额外子宫手术。
  • 与子宫肌瘤剔除术相比,RFA的再治疗率更高(HR 1.61,95% CI 1.08-2.40)。
  • 基线接受子宫肌瘤剔除术者后续子宫切除术比例最低(10.9%),基线接受子宫内膜消融术者最高(22.2%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine risk of subsequent treatment after uterine-sparing procedures for uterine leiomyomata. METHODS: Study participants from two uterine leiomyomata procedure studies were recontacted. The baseline procedures studied included myomectomy, endometrial ablation, laparoscopic ultrasound-guided radiofrequency ablation (RFA), and uterine artery embolization (UAE). Participants reported all uterine leiomyomata procedures after their baseline uterine-sparing leiomyomata procedure. The subsequent treatment options analyzed included the baseline uterine leiomyomata procedures plus hysterectomy and magnetic resonance imaging (MRI)-guided focused ultrasonography. Kaplan-Meier curves and Cox proportional hazards models were used to evaluate differences in retreatment risk according to baseline procedure by means of hazard ratios (HRs) and corresponding 95% CIs. Fisher exact tests were used to examine the association between baseline procedure and retreatment procedure. RESULTS: The total number of participants in the study is 817. Median age at baseline procedure was 39.7 years; participant median age at recontact was 46.8 years. Follow-up after baseline procedure was 4.0-10.5 years. Baseline procedure types included myomectomy (n=469, 66.0%), endometrial ablation (n=90, 12.7%), RFA (n=96, 13.5%), and UAE (n=56, 7.9%). Of the 204 participants (28.7%) who had retreatment for uterine leiomyomata, the most common subsequent procedure was hysterectomy (n=94, 46.1%), followed by myomectomy (n=57, 27.9%), UAE (n=26, 12.7%), endometrial ablation (n=12, 5.9%), MRI-guided focused ultrasonography (n=9, 4.4%), and RFA (n=6, 2.9%). Within 5 years after the baseline procedure, 79.1% (95% CI, 76.2-82.1%) had no additional uterine procedures; 64.1% (95% CI, 57.7-71.2%) had none within 10 years. When endometrial ablation, RFA, and UAE were compared with myomectomy, RFA was found to have a higher retreatment rate (HR 1.61, 95% CI, 1.08-2.40). Those who had undergone myomectomy at baseline were the least likely (10.9%) and those who had undergone endometrial ablation were most likely (22.2%) to have a subsequent hysterectomy. CONCLUSION: The majority of women who have uterine-sparing uterine leiomyomata procedures can remain treatment free for 5-10 years. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT06430320.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Graham McNeil K, Sitarik AR, Vines AI, et al. Patient Report of Subsequent Uterine-Sparing Leiomyomata Procedures up to 10 Years. Obstet Gynecol. 2026. PMID: 43008239. doi:10.1097/AOG.0000000000006459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。